Phase II Study of Nab-Sirolimus for Patients with Worsening or Symptomatic Epithelioid Hemangioendothelioma

Inclusion Criteria

• Must have a confirmed diagnosis of EHE that is worsening or causing symptoms and cannot be treated with surgery.
• Must have at least one tumor that can be measured accurately by scans or exams.
• Must be 18 years or older.
• Must be in relatively good health with an ECOG performance status of 0 to 2.
• Must have adequate blood and organ function, including:
  • Platelet count above 75,000
  • Neutrophil count above 1,500
  • Hemoglobin level above 9 g/dL
  • Creatinine level within normal limits or creatinine clearance above 30
  • Bilirubin level less than twice the normal limit
  • Liver enzymes (AST/ALT) less than three times the normal limit
• Must have recovered from any side effects of previous treatments to a mild level, except for hair loss or nerve damage.
• Women and men must agree to use effective birth control during the study and for a period after the study.
• Women of childbearing potential must have a negative pregnancy test before starting the study.
• Must be able to understand and sign a consent form to participate in the study.

Exclusion Criteria

• Cannot have an active, uncontrolled infection or severe heart failure.
• Cannot have active hepatitis B or C infections unless they are controlled.
• Cannot have had major surgery within 28 days before starting the study.
• Cannot have active brain disease or severe past brain-related side effects from drugs.
• Cannot have psychiatric or substance abuse issues that would interfere with the study.
• Cannot have had a heart attack within the last 12 months.
• Cannot have other active cancers or be taking other cancer treatments, except for certain hormone therapies.
• Pregnant women cannot participate due to potential risks to the baby.